How to Read a Peptide COA

What a peptide COA is meant to prove

A certificate of analysis (COA) is a batch-specific record summarising analytical tests performed on a material before release. For research peptides, the two most important fields are usually purity by HPLC and identity by mass spectrometry. Purity answers whether the main peak dominates the chromatogram. Identity answers whether the measured molecular mass matches the expected compound. Together, these fields support batch identification for laboratory intake and procurement files.

A COA is not a claim of medical safety, clinical efficacy, sterility, or suitability for human or veterinary use. HALO materials remain research-use-only (RUO) regardless of the purity number reported. The document is designed for chain-of-custody and research-material verification, not therapeutic decision-making.

The fields that matter first

• Product name and sequence: confirms the document is attached to the correct compound and, for peptides, the expected amino-acid sequence where applicable.
• Lot or batch number: must match the vial label and packing record. If the number differs, treat the document as unmatched until reconciled.
• Test method: HPLC should identify the column type, wavelength, gradient or method reference, and integration basis. Mass spectrometry should report the observed mass or ion species.
• Purity result: generally reported as peak-area percentage. A result of 98 percent means the main integrated peak represents 98 percent of detected chromatographic area under that method, not 98 percent clinical potency.
• Analyst, lab, or release date: establishes when the batch was tested and who generated the record.

How to read HPLC purity

HPLC separates components by interaction with a stationary phase and mobile-phase gradient. On a peptide COA, the main peak should appear at a defined retention time with minor peaks integrated separately. The purity percentage is normally calculated by peak-area normalization: main-peak area divided by total detected peak area. This is a powerful comparative quality signal, but it depends on wavelength, gradient, column, injection amount, and integration settings.

For procurement review, look for a clear chromatogram, a stated purity percentage, and method details sufficient to reproduce the measurement. A COA that lists only a purity number without method context is weaker than a document that includes chromatographic evidence.

Why mass spectrometry matters

HPLC purity alone does not prove identity. A pure wrong compound can still produce a clean peak. Mass spectrometry helps close that gap by checking observed molecular mass against the expected sequence or formula. For many peptides, the COA may report [M+H]+, [M+2H]2+, or other ion states. The observed value should align with the expected molecular weight within the laboratory method tolerance.

Common red flags

• COA does not include a lot number.
• Vial lot number and COA lot number do not match.
• Purity is stated without an HPLC method or chromatogram.
• Identity is stated without mass-spectrometry evidence or expected MW comparison.
• Document uses clinical language such as dosage, treatment, patient, or therapeutic outcome.
• COA is reused across multiple products, sizes, or lots.

What a COA cannot prove

A standard peptide COA does not automatically establish sterility, endotoxin status, residual solvents, microbial bioburden, or long-term stability unless those specific tests are listed. It also does not override the product label. If a vial is labelled RUO, the material is limited to qualified laboratory research even when purity is high and identity is confirmed.